论文部分内容阅读
将40例早期DN患者随机分为对照组和治疗组,对照组为常规西药治疗,治疗组在此基础上加用EGB,疗程均为2周,用酶联免疫吸附法(ELISA)测定两组患者治疗前后血清C反应蛋白CRP)、白细胞介素-6(IL-6)表达水平。结果:与治疗前比较,两组患者治疗后血清CRP、IL-6水平均下降(P<0.05),经q检验显示,治疗组较对照组下降更为明显(P<0.05)。结论:EGB可通过降低早期糖尿病肾病患者血清CRP、IL-6的表达,抑制炎症反应,起到对DN的保护作用。
Forty patients with early DN were randomly divided into control group and treatment group. The control group was treated with conventional western medicine. The treatment group was given EGB on the basis of the above two courses of treatment for two weeks. ELISA and enzyme-linked immunosorbent assay (ELISA) Serum C-reactive protein (CRP) and interleukin-6 (IL-6) expression levels in patients before and after treatment. Results: Compared with those before treatment, serum CRP and IL-6 levels decreased after treatment in both groups (P <0.05). The q test showed that the treatment group decreased more significantly than the control group (P <0.05). Conclusion: EGB can protect DN by decreasing the expression of CRP and IL-6 and inhibiting the inflammatory reaction in patients with early diabetic nephropathy.